证券代码：688366 证券简称：昊海生科 公告编号：2025-018 上海昊海生物科技股份有限公司 关于变更注册资本并修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海昊海生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第五届董事会第三十一次会议，审议通过了《关于变更公司注册资本并修 订公司章程的议案》等议案，现将相关事项公告如下： 一、变更注册资本 公司于 2024 年 5 月 29 日召开的 2023 年度股东周年大会、2024 年第一次 A 股类别股东大会及 2024 年第一次 H 股类别股东大会审议通过了《关于授予董事 会回购 H 股的一般性授权的议案》，并于 2024 年 6 月 3 日召开第五届董事会第 二十四次会议，审议通过了《关于上海昊海生物科技股份有限公司回购 H 股股 份的议案》。根据前述一般性授权和决议，公司于 2024 年 6 月 27 日至 2024 年 12 月 4 日期间合计回购 H 股股份 2,296,200 股，并分别于 2024 年 ...

Financial Performance - The company's operating revenue for 2024 reached RMB 2,697,657,908.35, representing a 1.64% increase compared to RMB 2,654,039,068.79 in 2023[22]. - The net profit attributable to shareholders for 2024 was RMB 420,446,906.16, a slight increase of 1.04% from RMB 416,121,340.71 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 379,096,331.64, showing a decrease of 1.12% compared to RMB 383,406,434.26 in 2023[22]. - The net cash flow from operating activities for 2024 was RMB 648,571,330.09, an increase of 2.23% from RMB 634,449,395.83 in 2023[22]. - As of the end of 2024, the net assets attributable to shareholders were RMB 5,575,258,634.87, a decrease of 1.32% from RMB 5,650,064,203.23 at the end of 2023[22]. - The total assets at the end of 2024 amounted to RMB 7,121,392,176.35, reflecting a slight increase of 0.22% from RMB 7,105,496,951.15 at the end of 2023[22]. - The company's gross profit margin for 2024 was 69.89%, slightly down from 70.46% in the previous year[32]. - The company achieved a revenue of 2,529.85 billion yuan in the pharmaceutical manufacturing industry in 2024, ranking 16th among 41 industrial categories, with a profit total of 342.07 billion yuan, a year-on-year decrease of 1.1%[80]. Dividend Distribution - The proposed cash dividend for the 2024 fiscal year is CNY 6.00 per 10 shares, totaling CNY 138,023,048.40 (including tax) based on a total share capital of 233,193,695 shares, after deducting 3,155,281 shares held in the repurchase account[8]. - The total cash dividend for 2024, including interim distributions, amounts to CNY 230,925,296.80, representing 54.92% of the net profit attributable to shareholders of the listed company[8]. - The company plans to submit the profit distribution proposal to the 2024 annual general meeting of shareholders for approval[8]. Research and Development - Research and development expenses for 2024 amounted to CNY 238.93 million, an increase of CNY 18.83 million, or approximately 8.56% year-on-year, representing 8.86% of total revenue[33]. - The company has a dedicated R&D team of 350 members, accounting for 16.23% of total employees, including 25 PhD holders and 107 master's degree holders[161]. - The company is actively pursuing clinical trials for various new products, including pain-reducing cross-linked sodium hyaluronate gel, which is currently in clinical testing[104]. - The company has established a comprehensive R&D management system and innovation incentive mechanism to enhance its technological capabilities[165]. - The company has filed for 56 new patents during the reporting period, with 59 patents granted, bringing the total to 468[98]. Product Development and Innovation - The company launched the world's first organic cross-linked hyaluronic acid product "Hai Mei Yue Bai" in July 2024, and received approval for its ophthalmic sodium hyaluronate eye drops in March 2024[33]. - The company is focusing on the integration of technologies such as stem cells, tissue engineering, and 3D printing to expand the application of biomedical materials in medical fields[86]. - The company is currently developing new products, including hydrophilic continuous vision intraocular lenses and collagen solutions for skin care, with R&D investments starting in 2024[178]. - The company is advancing various projects in the ophthalmology field, with multiple artificial lens products completing clinical trials and receiving regulatory certifications in early 2025[162]. - The company has developed a patented technology for medical chitosan, which has won multiple national awards, highlighting its innovation capabilities[107]. Market Position and Strategy - The company is committed to maintaining compliance with regulatory standards set by the National Medical Products Administration (NMPA)[16]. - Future outlook includes market expansion strategies and potential mergers and acquisitions to enhance competitive positioning[16]. - The company aims to leverage its research capabilities to drive innovation in medical devices and biopharmaceuticals[16]. - The company is focusing on four major therapeutic areas: medical aesthetics, ophthalmology, orthopedics, and adhesion prevention, which are expected to drive future growth[145]. - The company is actively engaged in the development of new products and technologies, focusing on the biomedical sector[192]. Compliance and Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[7]. - The board of directors and supervisory board members confirm the authenticity, accuracy, and completeness of the annual report[4]. - The governance structure is designed to ensure clear responsibilities and effective decision-making processes within the company[197]. Risks and Challenges - The company faces risks related to technological advancements in the biomedical materials field, which could impact its market competitiveness if it fails to adapt[115]. - The company is exposed to operational risks, including potential product quality issues that could lead to recalls and reputational damage[116]. - The company is affected by industry risks due to ongoing reforms in the pharmaceutical and medical device sectors, which may increase compliance costs and reduce product demand[117]. - The company's growth is partially dependent on the overall growth of the biopharmaceutical industry in China, which could slow down due to various factors[118]. - The company has pursued international expansion through acquisitions, which may be impacted by changes in foreign regulations or geopolitical tensions[118].

2024 年 報 目 錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 主席致辭 | 5 | | 管理層討論與分析 | 7 | | 董事會報告 | 25 | | 企業管治報告 | 53 | | 董事、監事及高級管理人員簡介 | 73 | | 獨立核數師報告 | 80 | | 綜合損益及其他綜合收益表 | 86 | | 綜合財務狀況表 | 88 | | 綜合權益變動表 | 90 | | 綜合現金流量表 | 92 | | 財務報表附註 | 95 | | 釋義 | 195 | | 技術詞彙 | 199 | 上海昊海生物科技股份有限公司 2 公司資料 第五屆董事會 執行董事： 侯永泰博士 （主席） 吳劍英先生 （總經理） 陳奕奕女士 唐敏捷先生 （財務總監） 非執行董事： 游捷女士 黃明先生 獨立非執行董事： 沈紅波先生 姜志宏先生 蘇治先生 楊玉社先生 趙磊先生 第五屆監事會 劉遠中先生 （主席） 楊青女士 唐躍軍先生 魏長征先生 宋霄女士 授權代表 黃明先生 趙明璟先生 聯席公司秘書 田敏女士 趙明璟先生 （香港公司治理公會資深會員） 審計委員會 沈紅波先生（ 主席） 游捷女 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-017 上海昊海生物科技股份有限公司 第五届监事会第二十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海昊海生物科技股份有限公司（以下简称"公司"）第五届监事会第二十 一次会议（以下简称"本次会议"）于2025年4月25日15:00时以现场结合通讯方 式召开，本次会议通知已于2025年4月11日以书面方式送达公司全体监事。本次 会议由监事会主席刘远中先生主持，会议应参加监事5人，实际参加监事5人。本 次会议的召集、召开符合《中华人民共和国公司法》等法律、法规和《上海昊海 生物科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 经与会监事审议，做出以下决议： 1.审议通过《关于公司2025年第一季度报告的议案》 监事会认为：公司2025年第一季度报告的编制和审议程序符合法律、法规、 《公司章程》和公司内部管理制度的各项规定； 公司2025年第一季度报告的内容与格式符合上海证券交易所 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司第 五屆監事會第二十一次會議決議公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年4月25日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士及黃明先生；及本公司之獨立非執 行董事為沈紅波先生、姜志宏先生、蘇治先生、楊玉社先生及趙磊先生。 * 僅供識別 证券代码：688366 证券简称：昊海生科 公告 ...

Financial Performance - The company's operating revenue for Q1 2025 was RMB 618,542,128.87, a decrease of 4.25% compared to RMB 645,995,271.22 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2025 was RMB 90,312,072.67, down 7.41% from RMB 97,541,532.98 year-on-year[9]. - The net profit after deducting non-recurring gains and losses was RMB 88,474,729.61, reflecting a decrease of 7.08% compared to RMB 95,217,851.02 in the previous year[9]. - The total revenue for the first quarter of 2025 was CNY 618,542,128.87, a decrease of approximately 4.5% compared to CNY 645,995,271.22 in the first quarter of 2024[24]. - The operating profit for the first quarter of 2025 was CNY 103,806,860.81, compared to CNY 114,427,839.61 in the first quarter of 2024, indicating a decline of approximately 9.1%[24]. - Net profit for Q1 2025 was approximately ¥83.81 million, a decrease of 9.1% compared to ¥92.49 million in Q1 2024[25]. - Total comprehensive income for Q1 2025 reached approximately ¥106.29 million, an increase of 49.2% from ¥71.27 million in Q1 2024[25]. - Basic and diluted earnings per share for Q1 2025 were both RMB 0.39, down 7.14% from RMB 0.42 in the same period last year[9]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.39, down from ¥0.42 in Q1 2024[25]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 13.04% to RMB 85,876,398.75, compared to RMB 75,969,702.64 in the same period last year[9]. - Cash flow from operating activities for Q1 2025 was approximately ¥85.88 million, an increase of 13.5% compared to ¥75.97 million in Q1 2024[28]. - Cash flow from investing activities for Q1 2025 showed a net outflow of approximately ¥179.29 million, compared to a net inflow of ¥159.29 million in Q1 2024[28]. - Cash flow from financing activities for Q1 2025 resulted in a net outflow of approximately ¥79.08 million, compared to a net inflow of ¥42.14 million in Q1 2024[29]. - The cash and cash equivalents as of March 31, 2025, were CNY 2,544,062,908.38, a decrease from CNY 2,630,205,433.37 as of December 31, 2024[21]. - The cash and cash equivalents at the end of Q1 2025 were approximately ¥944.67 million, an increase from ¥846.19 million at the end of Q1 2024[29]. Research and Development - Research and development expenses totaled RMB 48,418,019.42, a decrease of 25.40% from RMB 64,900,123.30 year-on-year[9]. - R&D expenses accounted for 7.83% of operating revenue, down from 10.05% in the previous year, a reduction of 2.22 percentage points[9]. - The company reported a decrease in R&D expenses to CNY 48,418,019.42 in the first quarter of 2025, down from CNY 64,900,123.30 in the same period last year, reflecting a reduction of approximately 25.5%[24]. Assets and Equity - Total assets at the end of the reporting period were RMB 7,127,388,076.14, a slight increase of 0.08% from RMB 7,121,392,176.35 at the end of the previous year[9]. - Equity attributable to shareholders increased by 1.68% to RMB 5,669,029,445.16 from RMB 5,575,258,634.87 at the end of the previous year[9]. - The total liabilities as of March 31, 2025, were CNY 1,175,145,054.36, a decrease from CNY 1,204,351,783.01 as of December 31, 2024[22]. - The equity attributable to shareholders as of March 31, 2025, was CNY 5,669,029,445.16, an increase from CNY 5,575,258,634.87 at the end of 2024[22]. Inventory and Costs - The company's inventory as of March 31, 2025, was CNY 488,198,643.67, slightly down from CNY 490,650,955.52 at the end of 2024[21]. - The total operating costs for the first quarter of 2025 were CNY 510,997,863.52, down from CNY 535,026,579.06 in the same period last year, reflecting a reduction of about 4.5%[24]. - The company experienced a significant increase in other comprehensive income, with a net amount of approximately ¥22.48 million in Q1 2025, compared to a loss of ¥21.22 million in Q1 2024[25]. Capital Changes - The company completed a capital reserve conversion to increase share capital, issuing 66,782,692 new shares in 2024[9].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 修訂《公司章程》 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據香港聯合交易所有限 公司證券上市規則第13.51(1)條而作出。 茲提述本公司於2024年5月29日召開之2023年度股東週年大會、2024年第一次A 股類別股東大會及2024年第一次H股類別股東大會審議通過的關於授予本公司董 事會（「董事會」）回購H股的一般性授權的議案（「2024年回購授權」）。根據2024年 回購授權，本公司於自2024年6月27日至本公告日的期間共計回購2,629,100股H 股，其中2,296,200股H股已完成註銷。 上述2,296,200 股H股註銷完成後，本公司股份總數由 235,489,895 股變更 為 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥618,542,128.87, a decrease of 4.25% compared to ¥645,995,271.22 in the same period last year[4] - The net profit attributable to shareholders was ¥90,312,072.67, down 7.41% from ¥97,541,532.98 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥88,474,729.61, reflecting a decrease of 7.08% compared to ¥95,217,851.02 in the previous year[4] - Total revenue for Q1 2025 was ¥618.54 million, a decrease of 4.9% compared to ¥645.99 million in Q1 2024[16] - Net profit for Q1 2025 was ¥83.81 million, a decline of 9.4% from ¥92.49 million in Q1 2024[16] - Basic earnings per share for Q1 2025 were ¥0.39, compared to ¥0.42 in Q1 2024[17] Cash Flow - The net cash flow from operating activities increased by 13.04% to ¥85,876,398.75, compared to ¥75,969,702.64 in the same period last year[4] - In Q1 2025, the net cash flow from operating activities was ¥85,876,398.75, an increase of 13.5% compared to ¥75,969,702.64 in Q1 2024[19] - Total cash inflow from operating activities was ¥640,948,930.38, down 9.1% from ¥705,232,753.89 in the previous year[19] - The net cash flow from investing activities was -¥179,294,387.16, a significant decrease from ¥159,290,447.77 in Q1 2024[19] - The net cash flow from financing activities was -¥79,079,486.98, compared to a positive cash flow of ¥42,137,675.19 in Q1 2024[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,127,388,076.14, a slight increase of 0.08% from ¥7,121,392,176.35 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to ¥7.13 billion, slightly up from ¥7.12 billion at the end of 2024[14] - Total liabilities decreased to ¥1.18 billion as of March 31, 2025, from ¥1.20 billion at the end of 2024[14] - The company’s total equity increased to ¥5.95 billion as of March 31, 2025, from ¥5.92 billion at the end of 2024[14] Research and Development - Research and development expenses totaled ¥48,418,019.42, a decrease of 25.40% from ¥64,900,123.30 year-on-year[4] - Research and development expenses for Q1 2025 were ¥48.42 million, a decrease of 25.5% from ¥64.90 million in Q1 2024[16] - The proportion of R&D expenses to operating revenue was 7.83%, down from 10.05% in the previous year, a reduction of 2.22 percentage points[4] Inventory and Cash Equivalents - The company reported an increase in inventory to ¥488.20 million as of March 31, 2025, compared to ¥490.65 million at the end of 2024[13] - Cash and cash equivalents were ¥2.54 billion as of March 31, 2025, down from ¥2.63 billion at the end of 2024[13] - The total cash and cash equivalents at the end of Q1 2025 were ¥944,673,243.30, an increase from ¥846,192,318.84 in Q1 2024[20] Non-Recurring Gains - The company reported non-recurring gains of ¥1,837,343.06 for the period, primarily from government subsidies and asset disposals[7]

上海昊海生物科技股份有限公司章程 1 | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 5 | | 第三章 | 股份和注册资本 | 5 | | 第四章 | 减资和购回股份 | 10 | | 第五章 | 股票和股东名册 | 11 | | 第六章 | 股东的权利和义务 | 12 | | 第七章 | 股东大会 | 15 | | 第八章 | 类别股东表决的特别程序 | 30 | | 第九章 | 董事会 | 32 | | 第十章 | 公司董事会秘书 | 40 | | 第十一章 | 公司总经理 | 40 | | 第十二章 | 监事会 | 42 | | 第十三章 | 公司董事、监事、总经理和其他高级管理人员的资格和义务 | 45 | | 第十四章 | 财务会计制度与利润分配 | 47 | | 第十五章 | 会计师事务所的聘任 | 52 | | 第十六章 | 公司的合并与分立 | 52 | | 第十七章 | 公司的解散和清算 | 53 | | 第十八章 | 通知与公告 | 55 | | 第十九章 | 公司章程的修订程序 | 57 | | 第二十章 | 附则 | 57 ...

昊海生科公告，2025年第一季度营收为6.19亿元，同比下降4.25%；净利润为9031.21万元，同比下降 7.41%。 ...